Rate My Professor Philip Evans

Professor Philip Evans is Emeritus Professor of Medical Radiation Imaging at the University of Surrey's Centre for Vision Speech and Signal Processing (CVSSP). He holds the title of CVSSP and NPL Professor of Medical Imaging since January 2018. Evans earned his DPhil from the University of Oxford and his first degree from the University of Aston. He joined the University of Surrey in 2012, bringing over 25 years of experience in medical radiation imaging and radiotherapy technology. In his career, he serves as joint chair of Workstream 4 and an Executive Board Member of the National Cancer Research Institute's CTRad (Clinical and Translational Radiotherapy Research Working Group) since 2015. He is also a member of the Trial Management Group for the IMPORT LOW and IMPORT HIGH Breast Radiotherapy Trials. His professional qualifications include DPhil, CPhys, CMath, FInstP, FIMA, and FIPEM.

Evans specializes in the application of physics and engineering to medical imaging problems, particularly in radiotherapy. His research encompasses quantitative radiomics methods for cancer applications, such as lung cancer biomarkers using metabolism and texture features; imaging during breast radiotherapy treatment as in the IMPORT HIGH trial; standardisation of imaging and treatment in MRI-guided radiotherapy in collaboration with Elekta and the National Physical Laboratory; ultrasound approaches for image-guided brachytherapy; and proton beam radiotherapy imaging methods as part of the Pravda consortium for 3D proton beam images. Key publications include 'Assessing small-lesion detectability and acquisition time optimisation in silicon-detector-Based PET: a phantom study' (Nicholas Thomas Leybourne et al., 2025); 'Enhanced performance characteristics of digital PET for small feature detection relative to non-digital PET' (Nicholas Leybourne et al., 2024); 'Models of the light output from scintillation crystals' (P. Evans and A. Mosleh-Shirazi, 2005); 'Tumour bed delineation for partial breast/breast boost radiotherapy: What is the optimal number of implanted markers?' (AM Kirby et al., 2013); and 'Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results' (Charlotte E. Coles et al., 2017, The Lancet). His work has contributed to advancements in accurate radiotherapy delivery and clinical trials influencing breast cancer treatment protocols.